Q-omics provides the consensus-scored LCN12 profile across patient tissues and cancer cell-line models. LCN12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LCN12 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, LCN12 RNA expression shows 16,524 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where LCN12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCN12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCN12 survival associations across molecular data types. LCN12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCN12 RNA expression–survival associations across cancer types. High LCN12 expression shows unfavorable associations in ACC, but favorable associations in SCLC, BLCA, STAD, SKCM and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LCN12 RNA expression.
This table summarizes LCN12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LCN12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCN12 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in COAD, LUAD and THCA. The KIRC box plot shows higher LCN12 RNA expression in normal versus tumor tissue (log2 FC = −1.368, t-test p < 0.001).
This table shows molecular features associated with LCN12 in patient tissues and cancer cell lines. In patient samples, LCN12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LCN12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
